"Number of ADSs outstanding on a fully diluted basis as of June 30, 2021 was 12,584,362 (or 251,687,240 ordinary shares) which includes 699,806 ADSs (or 13,996,120 ordinary shares) sold during the quarter ended June 30, 2021 under the Company's ATM program"
https://finance.yahoo.com/news/chemomab-therapeutics-announces-second-quarter-120000199.html
Recent CMMB News
- Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update • GlobeNewswire Inc. • 04/24/2024 11:00:00 AM
- Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis • GlobeNewswire Inc. • 04/18/2024 11:00:00 AM
- Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis • GlobeNewswire Inc. • 03/25/2024 11:06:46 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 12:00:10 PM
- Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update • PR Newswire (US) • 03/07/2024 12:00:00 PM
- Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference • PR Newswire (US) • 03/05/2024 12:00:00 PM
- Biotech Shares Massively Bid Up Before Opening Bell • AllPennyStocks.com • 02/20/2024 02:20:00 PM
- Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases • PR Newswire (US) • 02/20/2024 12:00:00 PM
- Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update • PR Newswire (US) • 02/14/2024 12:00:00 PM
- Chemomab Therapeutics to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/05/2024 12:00:00 PM
- Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis • PR Newswire (US) • 01/30/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/03/2024 12:00:16 PM
- Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024 • PR Newswire (US) • 01/03/2024 12:00:00 PM
- Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis • PR Newswire (US) • 11/16/2023 12:00:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/15/2023 09:35:45 PM
- Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis • PR Newswire (US) • 11/15/2023 12:00:00 PM
- Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023 • PR Newswire (US) • 11/13/2023 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/09/2023 01:00:12 PM
- Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 11/09/2023 01:00:00 PM
- Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement • PR Newswire (US) • 11/06/2023 09:15:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/06/2023 05:15:25 AM
- Form F-3/A - Registration statement by foreign private issuers: [Amend] • Edgar (US Regulatory) • 10/30/2023 12:33:35 PM
- Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update • PR Newswire (US) • 10/30/2023 11:00:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM